We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Advancing the Possibility of Personalized Neoantigen Cancer Vaccines

Product News   Nov 12, 2019

 
Advancing the Possibility of Personalized Neoantigen Cancer Vaccines
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

New Collaboration Aims to Increase COVID-19 Reagent Production

Product News

OXGENE™ and The Native Antigen Company have announced a collaboration to scale up their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines.

READ MORE

Developing a COVID-19 Vaccine: Cobra Biologics Part of ChAdOx1 Consortium

Product News

Cobra Biologics has announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19 (ChAdOx1), for fast-tracked clinical trials for COVID-19.

READ MORE

OPENCORONA Consortium: Collaborating to Develop a COVID-19 Vaccine

Product News

Cobra and the Karolinska Institutet have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE